Professor Wen-lin Huang – We are the World

◉ Special Session: Unaddressed Prostate Issues Lead to Cancer | Latest Therapies Mean It's No Longer a Death Sentence

Distinguished Speaker: Professor Wen-lin Huang

Academician, European Academy of Sciences (Elected 2024).
Recipient, State Council Special Allowance | World-Renowned Scientist.
Lead Developer of China’s First Gene Therapy Drug (Recombinant Human Endostatin Adenovirus Injection) to Enter Phase III Clinical Trials.
Founder & Chairman, Guangzhou Dabo Biological Products Co., Ltd.

Speaker's Authoritative Background

Professor Huang Wenlin is a pioneer in the fields of tumor gene therapy and immunotherapy.
He leads the Guangdong Provincial New Tumor Vaccine Engineering Laboratory and the Key Laboratory for Targeted Tumor Therapeutics, and previously served as Director of the Biological Therapy Center at Sun Yat-sen University Cancer Center.
He has achieved remarkable success in translating laboratory research into commercial products in gene therapy, oncolytic viruses, and CAR-NK cell therapy.
Under his leadership, five innovative products for tumor gene therapy and immunotherapy have progressed to the clinical stage, setting a benchmark for innovation and translation in China’s biopharmaceutical sector.
A prolific academic, Professor Huang served as chief editor of national textbooks like Molecular Virology and has authored or co-authored over 180 SCI-indexed papers in top-tier journals such as Nature Medicine, Nature Communications, and PNAS, boasting an H-index of 58.

Core Session Content

Theme: New Breakthroughs in Gene and Immunotherapy for Advanced Prostate Cancer

1. Overview of Cutting-Edge Therapies

PSMA-Targeted Therapy: A targeted infusion therapy that delivers radiation directly to prostate cancer cells, shown to extend survival for many patients with metastatic prostate cancer.
Combined Gene and Immunotherapy Strategies: Explore the latest advances and combination regimens utilizing gene therapeutics and immunotherapies like autologous Natural Killer (NK) cells injections for advanced prostate cancer.

2. The Practice of Precision Medicine

Biomarker-Guided Treatment: Learn how genetic testing (e.g., for mutations in genes like BRCA1, BRCA2, ATM) can match patients to more effective treatments, such as PARP inhibitors or immunotherapy, enabling personalized care.
Balancing Efficacy and Quality of Life: Analyze how these innovative therapies not only improve outcomes but also significantly reduce side effects commonly associated with traditional treatments
(like surgery, radiotherapy), such as incontinence and sexual dysfunction, helping patients maintain a high quality of life while extending survival.

3. Analysis of Latest Clinical Data

Professor Huang will present Phase II clinical trial data for the first time from his team’s novel gene therapy drug for different cancers.
Interpreting new global standards of care, such as those brought by recently FDA-approved drugs

Don't miss: November 11th at 2 PM

Unprecedented! Top eight experts from around the world discuss a new paradigm for the comprehensive prevention and treatment of cancer.”

◉ Target Audience

Individuals concerned about prostate health, cancer/prostate cancer patients, and their families.

Biopharmaceutical company executives, professional investors, and industry analysts.

Clinical practitioners and researchers in Urology and Oncology.

Anyone interested in the advancements of cutting-edge cancer treatment technologies.

Theme: Unprecedented! Eight World-Leading Experts Explore a New Paradigm for Full-Cycle Cancer Prevention and Treatment

Core Value of the Conference

This marks the first time in medical history that eight top experts from fields such as gene therapy, immune cell therapy, integrative medicine, and natural therapy have gathered for a summit dialogue. From cancer prevention to advanced treatment, this conference will present a comprehensive solution.

Panel of Authoritative Experts

Gene Therapy Pioneer - Prof. Wenlin Huang

Developer of China’s first gene therapy drug
Academician of the European Academy of Sciences
Expertise: Gene therapy and攻克 solid tumors

Integrative Medicine - Dr. Marcelo Lam

Pioneer in integrated Chinese-Western medicine
Advocate of Artemisinin’s anticancer applications
Expertise: Fusion of traditional and modern medicine

Cryotherapy & Bacterial Therapy Prof. Kecheng Xu

International authority in cryotherapy and bacterial therapy
100,000+ clinical case experiences
Expertise: Comprehensive treatment of advanced tumors

International Diagnosis & Treatment - Prof. Dinggang Li

International multidisciplinary consultation (MDT) expert
3,000+ international case experiences
Expertise: Personalized precision medical solutions

Prevention Pioneer - Prof. Qingyi Wei

Founder of molecular epidemiology
First to elucidate DNA repair mechanisms
Expertise: Cancer risk assessment and early prevention

Immunotherapy Prof. Minghui Zhang

Inventor of vNKT cell technology
Validated by 1,000+ clinical cases
Expertise: Novel strategies in tumor immunotherapy

Immunotherapy Prof. Minghui Zhang

Inventor of vNKT cell technology
Validated by 1,000+ clinical cases
Expertise: Novel strategies in tumor immunotherapy

Immunotherapy Prof. Minghui Zhang

Inventor of vNKT cell technology
Validated by 1,000+ clinical cases
Expertise: Novel strategies in tumor immunotherapy

Precision Diagnosis - Prof. Yufei Fan

Leader in HIFU non-invasive technology
Completed 1,000+ malignant tumor treatments
Expertise: Early diagnosis and non-invasive treatment

Panel of Authoritative Experts

Chapter 1: Scientific Cancer Prevention

How to nip cancer in the bud-from genetic testing to lifestyle interventions:

Guidance from molecular epidemiology
Natural therapies and immune enhancement
Modern applications of TCM’s “preventive treatment”

Chapter 2: Precision Diagnosis

How modern technology enables ultra-early detection:

Breakthroughs in imaging technology
Advances in minimally invasive diagnostics
Early warning through integrated Chinese-Western medicine

Chapter 3: Multi-Dimensional Treatment

How eight technological pathways collaborate in synergy:

Breakthrough progress in gene therapy
Clinical achievements in cell immunotherapy
Advantages of integrated Chinese-Western medicine
Innovations in localized treatment technologies

Chapter 4: Breakthroughs in Advanced Cancer

What tools remain when cancer reaches an advanced stage:

Experience in managing complex cases
Strategies for improving quality of life
Real-world cases of long-term survival

Conference Highlights

First-time disclosure of multiple Phase II clinical data
Eight experts sharing joint consultation insights live
Real recovery stories from advanced cancer patients
Launch of the global inaugural Cancer Prevention and Treatment Integration Initiative

Conference Details

Time: November 11, 2025, 14:00 – 15:30
Venue: Main Hall A
Format: Summit Dialogue + Case Analysis + Full Audience Interaction

Target Audience

Cancer patients and their families
Clinical doctors and scientific researchers
Biopharmaceutical investors
Health management practitioners
General public interested in health

Key Highlights of the Session

Unprecedented Expert Lineup: Eight top scholars covering the entire cancer prevention and treatment chain, enabling truly multidisciplinary integration.
Clash of Cutting-Edge Technology and Traditional Wisdom: Showcasing the full spectrum of human intelligence in fighting cancer-from the latest gene editing and cell immunotherapy to ancient TCM wisdom.
Interactive Sessions for Problem-Solving: Multiple interactive segments to ensure audience questions are authoritatively addressed.

A Fusion of Medicine and Humanity

A deep dialogue between tradition and innovation
A passionate collision of Eastern wisdom and Western technology
Seats are limited-grasp this opportunity to meet the world’s top experts face-to-face! Let us witness together the dawn of a new era in cancer prevention and treatment!

V1 Roundtable: Global Top-Tier Cancer Prevention & Treatment Strategy

Theme: Unprecedented! Eight World-Renowned Experts Explore a New Launch of the global Cancer Prevention & Treatment Integration Initiative

Event Details

Who Should Attend

A Convergence of Science and Humanity

This is where tradition meets innovation, and Eastern wisdom joins forces with Western technology.
Seats are limited-join this face-to-face dialogue with global pioneers and witness the dawn of a new era in cancer care.

Core Value

This summit marks an unprecedented gathering of eight leading experts across gene therapy, immune cell therapy, integrative Chinese-Western medicine, and natural therapies-delivering a comprehensive solution from cancer prevention to advanced treatment.

Gene Breakthrough – Prof. Huang Wenlin: Developer of China’s first gene therapy drug; Academician of the European Academy of Sciences and Arts.
Integrative Medicine Prof. [Name]: Pioneer in integrating traditional Chinese and Western medicine; early explorer of artemisinin’s anti-cancer applications.
Cryotherapy & Bacterial Therapy – Prof. Xu Kecheng: International authority with 100,000+ clinical cases.
International Diagnosis & Treatment – Prof. Li Dinggang: Multidisciplinary specialist with 3,000+ international case experiences.
Localized Innovation – Prof. Yu Baofa: Inventor of sustained-release library therapy; 100,000-case clinical database.
Prevention Pioneer – Prof. Wei Qingyi: Founder of molecular epidemiology; first to elucidate DNA repair mechanisms.
Immunotherapy – Prof. Zhang Minghui: Inventor of vNKT cell technology; 1,000+ clinical validations.
Precision Diagnosis – Prof. Fan Yufei: Leader in non-invasive HIFU technology; treated 1,000+ malignant tumors.

Scientific Prevention: From genetic testing to lifestyle interventions-how to stop cancer before it starts.
Precision Diagnosis: Advances in early detection via imaging, minimally invasive diagnostics, and integrated early warning systems.
Multimodal Treatment: Synergistic strategies across gene, immune cell, integrative medicine, and localized therapies.
Advanced-Stage Breakthroughs: Innovative approaches for late-stage cancer, quality-of-life enhancements, and long-term survival cases.

First disclosure of multiple Phase II clinical data
Live collaborative case discussions with eight experts
Real late-stage patient recovery case sharing